What is Concinnity Genetics?
Concinnity Genetics is at the forefront of revolutionizing gene therapy safety. Leveraging a cutting-edge AI platform combined with deep expertise in synthetic biology, the company designs novel control mechanisms. This technological prowess aims to address critical challenges in the safe and effective deployment of gene therapies, positioning Concinnity Genetics as a key innovator in the biotechnology landscape.
How much funding has Concinnity Genetics raised?
Concinnity Genetics has raised a total of $3.7M across 1 funding round:
Angel/Seed
$3.7M
Angel/Seed (2024): $3.7M with participation from Scottish Enterprise, Maven Capital, Old College Capital, and Eos Advisory
Key Investors in Concinnity Genetics
Scottish Enterprise
Founded in 1991, Scottish Enterprise is a national economic development agency and a non-departmental public body of the Scottish Government, likely supporting innovative companies within Scotland.
Maven Capital
Maven Capital is a flexible investor with a particular interest in healthcare and intellectual property-based opportunities, suggesting a focus on early-stage technologies within the pharmaceutical and medical device industries.
Eos Advisory
Eos Advisory is a Scottish investment firm focused on commercializing science and technology, with a portfolio emphasizing quality of life and environmental sustainability, indicating a strategic interest in impactful biotech innovations.
What's next for Concinnity Genetics?
The substantial capital infusion, particularly the recent strategic investment, signals a pivotal growth phase for Concinnity Genetics. This financing is expected to accelerate the development and commercialization of its AI-driven gene therapy control systems. The company is poised to expand its research and development capabilities, forge strategic partnerships, and scale its operations to meet the increasing demand for safer gene therapies. This strategic backing will likely enable Concinnity Genetics to solidify its market position and drive significant advancements in the field.
See full Concinnity Genetics company page
